Medical News / Reporting from ESC 2022 - Full-Dose Anticoagulation Lowers Thrombotic Event Risk in Patients with COVID-19

Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19. New findings suggest full-dose anticoagulation lowered the risk of venous and arterial complications by 44% compared with the standard-dose treatment of critically ill patients with COVID-19. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

On-demand treatment with vonoprazan completely resolved heartburn in less than 3 hours with sustained relief for ... read more
Once-weekly 2.4 mg semaglutide is associated with an approximate 60% reduced risk of type 2 diabetes in patients ... read more
Although the potential effects of global warming on human health continue to concern experts, the impact ... read more
Fish oil supplement intake may increase the long-term risk of atrial fibrillation (AF) in a healthy ... read more